| Bioactivity | JHU395 is an orally-bioavailable and a plasma stable lipophilic glutamine antagonists (GA) prodrug. JHU395 delivers 6-diazo-5-oxo-L-norleucine (DON) to malignant peripheral nerve sheath tumor (MPNST) in vitro and in vivo, and has antitumor activity in MPNST[1]. | ||||||||||||
| Name | JHU395 | ||||||||||||
| CAS | 2079938-92-2 | ||||||||||||
| Formula | C22H29N3O7 | ||||||||||||
| Molar Mass | 447.48 | ||||||||||||
| Appearance | Viscous liquid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lemberg KM, et al. The novel glutamine antagonist prodrug JHU395 has antitumor activity in malignant peripheralnerve sheath tumor. Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0319.2019. |